Nippon Shinyaku Co., Ltd. (4516) Press Release
Consolidated Financial Results for the First Quarter of Fiscal Year 2026(IFRS)
Earlier from Nippon Shinyaku
- Nippon Shinyaku: Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.
- Nippon Shinyaku: Enters into an Exclusive License Agreement for the Development, Manufacturing, and Commercialization of NS-025 Worldwide
- Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation
- Nippon Shinyaku: and Elixirgen Enter into an Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy